Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Researchers discover likely origin of epithelial ovarian cancer

Cornell University researchers have discovered a likely origin of epithelial ovarian cancer (ovarian carcinoma), the fifth leading cause of cancer death among women in the United States.

7 Mar 2013

SGO's 44th Annual Meeting on Women's Cancer to be held in Los Angeles

Ovarian cancer treatment, health care reform, the impact of obesity on gynecologic health and the delivery of high quality gynecologic cancer care highlight the Society of Gynecologic Oncology's (SGO) 44th Annual Meeting on Women's Cancer March 9-12 in Los Angeles.

6 Mar 2013

Viewpoints: Disappointing 'surprises' in health law; Cuts in graduate medical training threatens physician supply; Va. can afford Medicaid expansion

The proposed 2.3 percent reduction in (Medicare Advantage plan) payments, which comes on top of cuts already scheduled under the Affordable Care Act, pays no mind to the potential impact on quality of care throughout the program. These cuts will apply to all plans no matter the value they bring in providing quality care to beneficiaries or offering innovative solutions that could ultimately be scaled and applied to the broader program.

5 Mar 2013

AAP, ACMG release guidelines on best practices for genetic testing and screening of children

For the first time, the American Academy of Pediatrics (AAP) and the American College of Medical Genetics and Genomics (ACMG) spoke with one voice and released a set of recommendations and guidelines on best practices for genetic testing and screening of children.

5 Mar 2013

PDL BioPharma fourth quarter total revenues increase to $86.0 million

PDL BioPharma, Inc. (PDL) today reported financial results for the fourth quarter and full year ended December 31, 2012.

2 Mar 2013

Elevated cell sugar concentrations increase hyaluronan production and promote cancer growth

According to a recent University of Eastern Finland (UEF) study, elevated cell sugar concentrations increase the production of hyaluronan which, in turn, promotes cancer growth. Regulating the production of hyaluronan may be a way to prevent the spreading of cancer.

28 Feb 2013

Leading cancer researcher, Dr. Lewis Cantley, named a winner of the inaugural Breakthrough Prize in Life Sciences

Dr. Lewis Cantley, a leading cancer researcher credited with discovering a family of enzymes fundamental to understanding cancer, was named a winner of the inaugural Breakthrough Prize in Life Sciences, the world’s richest academic prize for medicine and biology. The prize, which carries a $3 million cash award, recognizes excellence in research aimed at curing intractable diseases and human life.

22 Feb 2013

Quest Diagnostics offers access to a new non-invasive prenatal test developed by Natera

Quest Diagnostics (NYSE:DGX), the world’s leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera.

From Quest Diagnostics 21 Feb 2013

Study finds little long-term survival advantage for women with ovarian cancer and BRCA mutations

Researchers at Moffitt Cancer Center and colleagues in Toronto and at Yale University studied the long-term survival of women with a BRCA1 or BRCA2 gene mutation who were diagnosed with invasive ovarian cancer. They found that the short-term benefit to having either mutation does not lead to a long-term survival benefit.

16 Feb 2013

Selumetinib shrinks tumors in women with low-grade ovarian cancer

Researchers at The University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix have discovered that many women with low-grade serous carcinoma of the ovary or peritoneum have seen their tumors stabilize or shrink after taking a regular dose of the compound selumetinib.

15 Feb 2013

Patient-specific cancer cell lines designed to predict chemotherapy sensitivity

In laboratory studies, scientists at the Johns Hopkins Kimmel Cancer Center have developed a way to personalize chemotherapy drug selection for cancer patients by using cell lines created from their own tumors.

15 Feb 2013

New drug delivery system can reduce size of ovarian tumors by as much as 83%

By loading fragile RNA into silicon nanoparticles, researchers from The Methodist Hospital and two other institutions found a new drug delivery system can reduce the size of ovarian tumors by as much as 83 percent -- and stop tumor growth in chemotherapy-resistant ovarian cancer tissue.

13 Feb 2013

New research to rewrite textbooks on how ovaries are formed

New research from the University of Adelaide will rewrite the textbooks on how an ovary is formed, as well as providing new insights into women's health and fertility.

13 Feb 2013

Researchers identify miR-506 as potential therapeutic candidate for metastatic ovarian cancer

Researchers employed an extensive analysis of genomic information to identify a new, high-risk cohort of ovarian cancer patients, characterize their tumors, find a potential treatment and test it in mouse models of the disease.

11 Feb 2013

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.

11 Feb 2013

Key details of how TRF2 protein performs crucial chromosome-protecting function

We take it for granted that our chromosomes won't stick together, yet this kind of cellular disaster would happen constantly were it not for a protein called TRF2. Now, scientists at The Scripps Research Institute (TSRI) have discovered key details of how TRF2 performs this crucial chromosome-protecting function.

7 Feb 2013

New method can determine seriousness of cancer prognosis with 80% certainty

The number of incorrect cancer prognoses can be halved with computerised image analysis. In three years time, the method can be used on patients with bowel cancer, ovarian cancer and prostate cancer.

6 Feb 2013

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Verastem, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.

5 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Researchers discover likely origin of epithelial ovarian cancer

SGO's 44th Annual Meeting on Women's Cancer to be held in Los Angeles

Viewpoints: Disappointing 'surprises' in health law; Cuts in graduate medical training threatens physician supply; Va. can afford Medicaid expansion

AAP, ACMG release guidelines on best practices for genetic testing and screening of children

PDL BioPharma fourth quarter total revenues increase to $86.0 million

Elevated cell sugar concentrations increase hyaluronan production and promote cancer growth

Leading cancer researcher, Dr. Lewis Cantley, named a winner of the inaugural Breakthrough Prize in Life Sciences

Quest Diagnostics offers access to a new non-invasive prenatal test developed by Natera

Study finds little long-term survival advantage for women with ovarian cancer and BRCA mutations

Selumetinib shrinks tumors in women with low-grade ovarian cancer

Patient-specific cancer cell lines designed to predict chemotherapy sensitivity

New drug delivery system can reduce size of ovarian tumors by as much as 83%

New research to rewrite textbooks on how ovaries are formed

Researchers identify miR-506 as potential therapeutic candidate for metastatic ovarian cancer

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Key details of how TRF2 protein performs crucial chromosome-protecting function

New method can determine seriousness of cancer prognosis with 80% certainty

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in